LRP4 is an entry receptor for multiple encephalitic alphaviruses
Encephalitic alphaviruses, including Eastern equine encephalitis virus (EEEV), cause severe neurological disease with high mortality rates, and thus are a public health threat. Although members of the low-density lipoprotein receptor (LDLR) family, including VLDLR, LRP8 (ApoER2), and LDLR recently were identified as receptors for EEEV, residual infection in receptor-deficient cells suggests that additional entry factors exist. Using a CRISPR-based activation screen, we identified LDLR-related protein 4 (LRP4) as a candidate entry factor for EEEV and several related alphaviruses (Western equine encephalitis, Semliki Forest, and Sindbis viruses). LRP4 mediates viral attachment and internalization, and its ligand-binding domain binds directly to virions. Soluble LRP4 decoy proteins potently inhibit EEEV infection in primary mouse neuronal cells, male mice, and human brain organoids, suggesting possible therapeutic applications. Mammalian and avian LRP4 orthologs demonstrate conserved functions in promoting EEEV infection, supporting a possible role in its host range of infection and transmission. Our findings establish LRP4 as a shared entry receptor for multiple alphaviruses and expand our understanding of alphavirus tropism, pathogenesis, and countermeasure development. In this study, the authors identify LRP4 as an entry receptor for Eastern equine encephalitis virus, and show that decoy proteins block infection in neuronal cells, mice, and brain organoids, and that it is conserved across birds and mammals indicating a potential role in host range and transmission.
Authors
- Sean Hui (ORCID: https://orcid.org/0000-0002-9870-6823)
- Bingting Ma (ORCID: https://orcid.org/0000-0001-9898-0999)
- Ye Xiang (ORCID: https://orcid.org/0000-0003-0230-9522)
- Yu-Yi Zhang (ORCID: https://orcid.org/0000-0001-5554-3756)
- Daved H. Fremont (ORCID: https://orcid.org/0000-0002-8544-2689)
- Alan Sariol (ORCID: https://orcid.org/0000-0002-3127-0543)
- Zhenlu Chong (ORCID: https://orcid.org/0000-0001-6195-3452)
- Zhuohao He (ORCID: https://orcid.org/0000-0003-1505-8750)
- William B. Klimstra
- Xinran Sun (ORCID: https://orcid.org/0000-0002-5177-0799)
- Sicheng Tian (ORCID: https://orcid.org/0000-0002-7134-9774)
- Jiayue Zhou (ORCID: https://orcid.org/0009-0008-0987-0527)
- Theron C. Gilliland
- Guojie Wang
- Yingxin Hu
- Rong Zhang (ORCID: https://orcid.org/0009-0003-4646-8434)
- Michael S. Diamond (ORCID: https://orcid.org/0000-0002-8791-3165)
- Hongyuan Guo
Institutions
- Shanghai Medical College of Fudan University (CN)
- University of Pittsburgh (US)
- Washington University in St. Louis (US)
- Fudan University (CN)
- Shanghai Institute of Organic Chemistry (CN)
- Shanghai Institute of Applied Physics (CN)
- Center for Life Sciences (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-06-09
- DOI
- https://doi.org/10.1038/s41467-026-73852-0
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Fudan University
- Ministry of Education, India
- Program of Shanghai Academic Research Leader